TAIPEI, June 11, 2015 /PRNewswire/ -- BRIM Biotechnology, Inc. ("BRIM"), announced today that it has entered a Collaboration, Option and License Agreement with Janssen Pharmaceutica N.V. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement, which was facilitated by Johnson & Johnson Innovation, the parties will pursue the research, development and commercialization of certain compounds identified by Janssen that are targeted for dengue indications.
Dr. Haishan Jang, BRIM's President and CEO, stated, "We are extremely excited and enthusiastic about working with Janssen in developing effective treatment for dengue. There is a high unmet medical need in dengue, especially in Asia. With Janssen's experienced Infectious Diseases team and BRIM's core competencies in translational sciences and integrated operation management in Asia, we are confident at progressing the compounds toward a high quality affordable drug candidate for Dengue disease."
About Dengue Disease
Dengue is ranked by WHO as the most important mosquito-borne viral disease, with approximately 2.5 billion people live in dengue endemic countries, and is seeing rapid and ongoing expansion related to increasing global spread of the viral vector. While WHO estimates suggest 50-100 million dengue infections occur annually, recent data from 2010 reported up to 390 million infections annually, with almost 100 million having symptoms of infection (Bhatt et al 2013, Nature). Global warming and intercontinental flights fuel the global spreading of this disease. Dengue is the leading cause for children hospitalization in Asia. The first dengue infection is generally a self-limiting, acute febrile illness. Subsequent infection with a different serotype can lead to severe disease (Dengue Hemorrhagic Fever), Dengue Shock Syndrome and even death.
BRIM (Beyond Research and Innovative Medicines), a preclinical/clinical development company focused on using translational sciences to develop affordable and high quality medicines, began operating in August 2013 and is based in Taipei, Taiwan. With a fully integrated Asia-based R&D operation team and a US-based senior scientific team experienced in all functional areas of drug development, BRIM is well poised to bring new therapies to the market.
For more information, please visit www.brimbiotech.com
Ms. Mei-Hui Kuo
TEL: +886-2-2788-8090 ext.110
SOURCE BRIM Biotechnology Inc.